Novel Therapeutic Agents for the Treatment of Prostate Cancer
Design and Development of Novel Anti-androgens, Thapsigargin Analogs and Inhibitors of Prostate Specific Antigen
Versandkostenfrei!
Versandfertig in 6-10 Tagen
45,99 €
inkl. MwSt.
PAYBACK Punkte
23 °P sammeln!
Standard hormonal therapy with currently available anti-androgens and LHRH analogs becomes ineffective in the hormone-refractory stage of prostate cancer due to the changes in androgen receptor signaling axis in prostate cancer cells. To develop effective therapies against hormone-refractory prostate cancer, novel agents targeting multiple points at the cellular signaling cascades are needed in order to produce the maximal therapeutic efficacy against late stage prostate cancer. In this dissertation work, we have presented the design and development of novel agents targeting three key signalin...
Standard hormonal therapy with currently available
anti-androgens and LHRH analogs becomes ineffective
in the hormone-refractory stage of prostate cancer
due to the changes in androgen receptor signaling
axis in prostate cancer cells. To develop effective
therapies against hormone-refractory prostate
cancer,
novel agents targeting multiple points at the
cellular signaling cascades are needed in order to
produce the maximal therapeutic efficacy against
late
stage prostate cancer. In this dissertation work, we
have presented the design and development of novel
agents targeting three key signaling pathways
towards
their ultimate development into the effective
therapies against hormone refractory prostate
cancer.
Specifically, we have discovered and designed a
diverse array of novel molecules targeting the AR
signaling pathway, the sarco-endoplasmic reticulum
calcium ATPase pump driven calcium homeostasis and
the proteolytic activity of prostate specific
antigen
.
anti-androgens and LHRH analogs becomes ineffective
in the hormone-refractory stage of prostate cancer
due to the changes in androgen receptor signaling
axis in prostate cancer cells. To develop effective
therapies against hormone-refractory prostate
cancer,
novel agents targeting multiple points at the
cellular signaling cascades are needed in order to
produce the maximal therapeutic efficacy against
late
stage prostate cancer. In this dissertation work, we
have presented the design and development of novel
agents targeting three key signaling pathways
towards
their ultimate development into the effective
therapies against hormone refractory prostate
cancer.
Specifically, we have discovered and designed a
diverse array of novel molecules targeting the AR
signaling pathway, the sarco-endoplasmic reticulum
calcium ATPase pump driven calcium homeostasis and
the proteolytic activity of prostate specific
antigen
.
Andere Kunden interessierten sich für
